Valuation: Kamada Ltd.

Market Cap 1.45B 0 475M 412M 389M 352M 661M 45.58B 666M 4.64B 1.79B 23.11B 1.78B 1.75B 73.7B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 1.45B 0 475M 412M 389M 352M 661M 45.58B 666M 4.64B 1.79B 23.11B 1.78B 1.75B 73.7B EV / Sales 2026 *
2.39x
EV / Sales 2027 * 2.15x
Free-Float
54.4%
Yield 2026 *
-
Yield 2027 * -
1 day-2.55%
1 week-1.89%
Current month-0.37%
1 month+6.73%
3 months+11.92%
6 months-12.04%
Current year+8.01%
1 week 2,401
Extreme 2401
2,552
1 month 2,200
Extreme 2200
2,578
Current year 2,013
Extreme 2013
2,890
1 year 1,956
Extreme 1956
2,890
3 years 1,685
Extreme 1685
3,045
5 years 1,309
Extreme 1309
3,045
10 years 1,309
Extreme 1309
4,500
Manager TitleAgeSince
Chief Executive Officer 58 2015-06-30
Director of Finance/CFO 56 2017-12-30
Chief Operating Officer 54 2016-10-31
Director TitleAgeSince
Director/Board Member 75 1990-12-12
Chairman 77 2013-03-06
Chairman 55 2020-08-11
Date Insider Type Main position Quantity % Market Cap. Importance
9/9/26 Sell

Founder

-175 0.0003%
9/2/26 Exercice

VP Quality

6,937 0.0120%
9/2/26 Exercice

Founder

107,166 0.1857%
Change 5-day change 1-year change 3-year change Capi.($)
-2.55%-1.89%+6.59%+22.42% 474M
-1.67%-3.52%+36.53%-5.06% 79.26B
-1.54%+2.75%+503.81%+25.83% 58.56B
+1.57%+0.62%-16.15%-34.72% 58.62B
-0.56%-3.68%-11.53%+25.63% 48.75B
-0.29%+1.45%+2.14%+149.29% 46.32B
-0.66%+1.76%+50.87%-15.13% 32.12B
-0.72%-2.55%+45.81%+93.81% 24.77B
-1.91%-6.22%-2.91%+151.66% 21.5B
-1.92%-3.81%+61.03%+96.07% 15.97B
Average -1.04%-1.63%+67.62%+50.98% 38.63B
Weighted average by Cap. -0.75%-1.82%+89.75%+35.94%

Financials

2026 *2027 *
Net sales 606M 0 199M 172M 163M 148M 277M 19.1B 279M 1.95B 749M 9.69B 748M 731M 30.89B 673M 0 221M 192M 181M 164M 308M 21.23B 310M 2.16B 832M 10.76B 831M 813M 34.32B
Net income 84.8M 0 27.87M 24.14M 22.83M 20.67M 38.79M 2.67B 39.08M 272M 105M 1.36B 105M 102M 4.32B 104M 0 34.22M 29.64M 28.03M 25.38M 47.63M 3.28B 47.99M 334M 129M 1.66B 129M 126M 5.31B
Net Debt - -
Logo Kamada Ltd.
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Employees
462
Date Price Change Volume
26-09-15 ILA 2,441.00 -2.55% 101,220
26-09-14 ILA 2,505.00 +2.16% 275,975
26-09-10 ILA 2,452.00 -1.53% 69,336
26-09-09 ILA 2,490.00 +0.08% 130,011
26-09-08 ILA 2,488.00 -0.12% 317,225
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. KMDA Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!